Response to anti-PD1 therapy with nivolumab in metastatic sarcomas

BACKGROUND: Manipulation of immune checkpoints such as CTLA4 or PD-1 with targeted antibodies has recently emerged as an effective anticancer strategy in multiple malignancies. Sarcomas are a heterogeneous group of diseases in need of more effective treatments. Different subtypes of soft tissue and...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Sarcoma Res
Asıl Yazarlar: Paoluzzi, L., Cacavio, A., Ghesani, M., Karambelkar, A., Rapkiewicz, A., Weber, J., Rosen, G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2016
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5200964/
https://ncbi.nlm.nih.gov/pubmed/28042471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-016-0064-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller